[HTML][HTML] Phase I study of vandetanib during and after radiotherapy in children with diffuse intrinsic pontine glioma
A Broniscer, JN Baker, M Tagen… - Journal of clinical …, 2010 - ncbi.nlm.nih.gov
Journal of clinical oncology, 2010•ncbi.nlm.nih.gov
Purpose To evaluate the safety, maximum-tolerated dose, pharmacokinetics, and
pharmacodynamics of vandetanib, an oral vascular endothelial growth factor receptor 2
(VEGFR2) and epidermal growth factor receptor inhibitor, administered once daily during
and after radiotherapy in children with newly diagnosed diffuse intrinsic pontine glioma.
pharmacodynamics of vandetanib, an oral vascular endothelial growth factor receptor 2
(VEGFR2) and epidermal growth factor receptor inhibitor, administered once daily during
and after radiotherapy in children with newly diagnosed diffuse intrinsic pontine glioma.
Abstract
Purpose
To evaluate the safety, maximum-tolerated dose, pharmacokinetics, and pharmacodynamics of vandetanib, an oral vascular endothelial growth factor receptor 2 (VEGFR2) and epidermal growth factor receptor inhibitor, administered once daily during and after radiotherapy in children with newly diagnosed diffuse intrinsic pontine glioma.
ncbi.nlm.nih.gov